First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients
AUTOR(ES)
Chachá, Silvana Gama Florencio, Rodrigues, João Paulo Vilela, Araújo, Roberta Chaves, Pereira, Leonardo Régis Leira, Villanova, Márcia Guimarães, Souza, Fernanda Fernandes, Santana, Rodrigo de Carvalho, Martinelli, Ana de Lourdes Candolo
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
2018-04
RESUMO
Abstract INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center. METHODS: A retrospective descriptive study was conducted in patients with HCV genotype 1 infection who started treatment between July 2013 and December 2015. Data were collected using a computerized system. RESULTS: A total of 115 subjects were included, of which 58 (50.4 %) had liver cirrhosis and 103 (89.6 %) used TVR. The overall SVR rate was 61.7 % (62.1 % for TVR and 58.3 % for BOC). The presence of cirrhosis was associated with a lower SVR rate, whereas patients who relapsed after prior therapy had a greater chance of showing SVR than did non-responders. The incidence of adverse drug reactions (ADRs) was high. Almost all patients (~100 %) presented with hematologic events. Furthermore, treatment had to be discontinued in 15 subjects (13 %) due to severe ADRs. CONCLUSIONS: In conclusion, the SVR rates in our study were lower than those reported in pre-marketing studies but were comparable to real-life data. ADRs, particularly hematological ADRs, were more common compared to those in previous studies and resulted in a high rate of treatment discontinuity.
Documentos Relacionados
- Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil
- Treating hidradenitis suppurativa patients with adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal
- Pegvisomant in acromegaly: a multicenter real-life study in Argentina
- Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study
- Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series